Canada Life’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Canada Life’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,572	Closed	-$9K	–	2564
2016 Q1	$9K	Hold	1,572	–	–	﹤0.01%	2415
2015 Q4	$27K	Hold	1,572	–	–	﹤0.01%	2324
2015 Q3	$33K	Hold	1,572	–	–	﹤0.01%	2234
2015 Q2	$77K	Hold	1,572	–	–	﹤0.01%	2030
2015 Q1	$122K	Hold	1,572	–	–	﹤0.01%	1669
2014 Q4	$95K	Hold	1,572	–	–	﹤0.01%	1798
2014 Q3	$67K	Buy	+1,572	New	+$84.4K	﹤0.01%	1925

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

TAM

Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Canada Life's OREX Position: Q2 2016 in Review

Canada Life sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2016, closing a stake of 1,572 shares — an estimated $9K sold.

Canada Life first reported a position in OREX in Q3 2014 and held it in 7 quarters. The position peaked at $122K in Q1 2015. 73 funds tracked by Wall St. Rank hold OREX as of Q2 2016.

Canada Life reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
Canada Life sold 1,572 Orexigen Therapeutics, Inc. shares in Q2 2016, an estimated $9K.
Canada Life first reported a position in Orexigen Therapeutics, Inc. in Q3 2014 and held it in 7 quarters.
Canada Life's Orexigen Therapeutics, Inc. position peaked at $122K in Q1 2015.
73 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2016.

Based on Canada Life's 13F filing for Q2 2016, filed 3 Aug 2016.